ATyr Pharma Alpha and Beta Analysis
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ATyr Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in ATyr Pharma over a specified time horizon. Remember, high ATyr Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ATyr Pharma's market risk premium analysis include:
Beta (0.43) | Alpha 0.45 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ATyr |
ATyr Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ATyr Pharma market risk premium is the additional return an investor will receive from holding ATyr Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ATyr Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ATyr Pharma's performance over market.| α | 0.45 | β | -0.43 |
ATyr Pharma Fundamentals Vs Peers
Comparing ATyr Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ATyr Pharma's direct or indirect competition across all of the common fundamentals between ATyr Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as ATyr Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ATyr Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ATyr Pharma to competition |
| Fundamentals | ATyr Pharma | Peer Average |
| Return On Equity | -0.56 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Operating Margin | (70.79) % | (5.51) % |
| Current Valuation | 55.05 M | 16.62 B |
| Shares Outstanding | 69.01 M | 571.82 M |
| Shares Owned By Insiders | 2.61 % | 10.09 % |
| Shares Owned By Institutions | 61.69 % | 39.21 % |
ATyr Pharma Opportunities
ATyr Pharma Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | aTyr Pharma to Present Poster Describing Efzofitimods Mechanism of Action at the American Thoracic Society 2024 International Conference | 05/15/2024 |
About ATyr Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ATyr or other delisted stocks. Alpha measures the amount that position in ATyr Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
ATyr Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of ATyr Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ATyr Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ATyr Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ATyr Pharma. Please utilize our Beneish M Score to check the likelihood of ATyr Pharma's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ATyr Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |